On March 20, CMS issued new guidance to Medicare Part D carriers that the program would cover anti-obesity medications if they are approved for cardiovascular benefits and used for patients with that condition. Currently, Novo Nordisk’s GLP-1 drug Wegovy is the only drug meeting those criteria following a recent FDA approval (covered in the previous edition of The Strategist). Medicare is still prohibited by law to cover the drugs for weight loss alone.